## Saudi Drug Updates (SDU)

Jan 2025 A monthly electronic bulletin published by the drug sector

## **Approved Clinical Trials on Drugs**

	Study Title	Investigational Medicinal Product	Sponsor / CRO	Study Sites
1	A Randomized, Double-Blinded, Placebo-Controlled, Phase 3, Parallel- Group Design Study Evaluating the Efficacy and Safety of Efgartigimod IV in Adult Participants With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis – Phase 3	Efgartigimod IV	Argenx BV / Balsam	King Faisal Specialist Hospital and Research Center (Riyadh)
2	The ENERGY 2 Study: An Open-Label Phase 3 Study to Evaluate the Efficacy and Safety of INZ-701 in Infants with Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency – Phase 3	INZ-701	Inozyme Pharma, Inc / PDC	King Faisal Specialist Hospital and Research Center (Riyadh)
3	Comparing the effectiveness of buccal infiltration of different volumes of Articaine for extraction of mandibular posterior teeth- A randomized clinical trial – Phase 4	Articaine hydrochloride, Epinephrine bitartrate	Dental Clinic-collage of Dentistry-Qassim Unviersity / N/A	Dental Clinic- collage of Dentistry- Qassim Unviersity (Al- Qassim)
4	Survey assessing prospective patient's short-term treatment satisfaction and Quality of Life in patients with Hidradenitis Suppurativa initiated on Cosentyx (Secukinumab) in routine clinical practice in Saudi Arabia - Phase 4	Secukinumab	Novartis / N/A	King Fahad Medical City (Riyadh)